RGNX(REGENXBIO Inc.) · 财务报表

RGNX(REGENXBIO Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$470.35M$112.72M$90.24M$83.33M$170.44M
毛利润$418.51M$58.18M$53.03M$49.76M—
营业利润$159.98M−$262.88M−$268.13M−$233.35M−$161.20M
净利润$127.84M−$280.32M−$263.49M−$227.10M−$193.88M
经营现金流$218.88M−$207.49M−$218.41M−$173.12M−$123.96M
自由现金流$134.70M−$238.21M−$228.37M−$175.56M−$126.38M
摊薄每股收益$2.91$-6.50$-6.02$-4.59$-3.76

REGENXBIO Inc. RGNX